Catalog # RSF-V52H8



Synonym	Purity
Prefusion glycoprotein F0/pre-F protein (RSV)	>95% as determined by SDS-PAGE.
Source	>90% as determined by SEC-MALS.
HRSV (B) Pre-fusion glycoprotein F0, His Tag (RSF-V52H8) is expressed from human 293 cells (HEK293).	Formulation
Molecular Characterization	Lyophilized from 0.22 μ m filtered solution in 0.1 M Sodium citrate, 150 mM
	NaCl, pH5.5 with trehalose as protectant.
This protein carries a polyhistidine tag at the C-terminus.	Contact us for customized product form or formulation.
The protein has a calculated MW of 56.3 kDa. The protein migrates as 60-65	Reconstitution
kDa when calibrated against Star Ribbon Pre-stained Protein Marker under	

reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per μg by the LAL method.

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:


- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE



HRSV (B) Pre-fusion glycoprotein F0, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With <u>Star Ribbon Pre-stained Protein Marker</u>).

SEC-MALS



The purity of HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) is more than 90% and the molecular weight of this protein is around 190-240 kDa verified by SEC-MALS.




Bioactivity-ELISA






Catalog # RSF-V52H8




Anti-Fusion glycoprotein F0 Antibody, Human IgG1 (D25) Conc. (μ g/mL)


Immobilized HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) at 1 μ g/mL (100 μ L/well) can bind Anti-Fusion glycoprotein F0 Antibody, Human IgG1 (D25) with a linear range of 0.008-0.25 μ g/mL (QC tested).




Immobilized HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) at 1 μ g/mL (100 μ L/well) can bind Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) with a linear range of 0.1-4 ng/mL (Routinely tested).

Bioactivity-SPR






Immobilized Recombinant Human Anti-RSV Antibody (AM14), Human IgG1 at 1 μ g/mL (100 μ L/well) can bind HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) with a linear range of 0.5-31 ng/mL (QC tested).



Immobilized Nirsevimab, Human IgG1 kappa at 1 μ g/mL (100 μ L/well) can bind HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) with a linear range of 0.2-16 ng/mL (Routinely tested).







Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) captured on Protein G-Series S sensor chip can bind HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) with an affinity constant of 0.766 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

>>> www.acrobiosystems.com






Monoclonal Anti-HRSV-A F/Fusion glycoprotein F0 Antibody, Human IgG1 (D25) captured on Protein G-Series S sensor chip can bind HRSV (B) Prefusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) with an affinity



300

400




RU 125 9 100 75 50 25 0

100

0

Monoclonal Anti-RSV-F0 broadly Antibody, Mouse IgG1 (4G2) captured on Protein G-Series S sensor chip can bind HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) with an affinity constant of 6.69 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).




Monoclonal Anti-RSV-F0 broadly Antibody, Mouse IgG1 (3B4) captured on CM5 chip via anti-mouse antibodies surface can bind HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) with an affinity constant of 2.58 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Background

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation. Both states exhibit epitopes targeted by neutralizing antibodies, and post-fusion RSV F is being developed as a vaccine candidate.

Clinical and Translational Updates

constant of 0.792 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).



200

Time



>>> www.acrobiosystems.com

